CHIASMA, INC DE false 0001339469 0001339469 2020-11-18 2020-11-18





Washington, D.C. 20549







Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): November 18, 2020



Chiasma, Inc.

(Exact name of registrant as specified in its charter)




DELAWARE   001-37500   76-0722250

(State or other jurisdiction

of incorporation)



File Number)


(I.R.S. Employer

Identification No.)

140 Kendrick Street, Building C East

Needham, Massachusetts 02494

(Address of principal executive office) (Zip Code)

(617) 928-5300

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class





Name of each exchange

on which registered

Common Stock, $0.01 par value    CHMA    NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒




Item 7.01

Regulation FD Disclosure.

Chiasma, Inc.’s management will host a conference call and webcast to discuss top-line results from its international Phase 3 clinical trial, referred to as the “MPOWERED” (Maintenance of Acromegaly Patients with Octreotide Capsules Compared With Injections - Evaluation of REsponse Durability), of MYCAPSSA® (octreotide capsules) for the maintenance treatment of adult patients with acromegaly on Wednesday, November 18, 2020 at 8:00 a.m. ET. A copy of the slide deck accompanying such presentation is being furnished as Exhibit 99.1, which is incorporated herein by reference.

The information set forth in Item 7.01 and Exhibit 99.1 is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.


Item 8.01

Other Events.

On November 18, 2020, Chiasma, Inc. issued a press release announcing top-line results from the MPOWERED trial of MYCAPSSA® for the maintenance treatment of adult patients with acromegaly. A copy of the press release is attached hereto as Exhibit 99.2 hereto and is incorporated herein by reference.


Item 9.01

Financial Statements and Exhibits.








99.1    Investor presentation furnished by Chiasma, Inc.
99.2    Press Release issued by Chiasma, Inc. dated November 18, 2020.
104    Cover Page Interactive Data File.


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: November 18, 2020     Chiasma, Inc.

/s/ Mark Fitzpatrick

      Mark Fitzpatrick